Lifecome Biochemistry Co Ltd (002868) - Net Assets
Based on the latest financial reports, Lifecome Biochemistry Co Ltd (002868) has net assets worth CN¥-104.52 Million CNY (≈ $-15.29 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.38 Billion ≈ $202.56 Million USD) and total liabilities (CN¥1.49 Billion ≈ $217.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Lifecome Biochemistry Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥-104.52 Million |
| % of Total Assets | -7.55% |
| Annual Growth Rate | N/A |
| 5-Year Change | -103.19% |
| 10-Year Change | -110.27% |
| Growth Volatility | 56.06 |
Lifecome Biochemistry Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Lifecome Biochemistry Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Lifecome Biochemistry Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Lifecome Biochemistry Co Ltd (2012–2024)
The table below shows the annual net assets of Lifecome Biochemistry Co Ltd from 2012 to 2024. For live valuation and market cap data, see Lifecome Biochemistry Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥-24.54 Million ≈ $-3.59 Million |
-105.92% |
| 2023-12-31 | CN¥414.11 Million ≈ $60.60 Million |
-30.90% |
| 2022-12-31 | CN¥599.30 Million ≈ $87.70 Million |
-17.00% |
| 2021-12-31 | CN¥722.02 Million ≈ $105.65 Million |
-6.22% |
| 2020-12-31 | CN¥769.94 Million ≈ $112.67 Million |
-1.10% |
| 2019-12-31 | CN¥778.50 Million ≈ $113.92 Million |
+5.15% |
| 2018-12-31 | CN¥740.37 Million ≈ $108.34 Million |
+6.42% |
| 2017-12-31 | CN¥695.68 Million ≈ $101.80 Million |
+156.39% |
| 2016-12-31 | CN¥271.34 Million ≈ $39.71 Million |
+13.54% |
| 2015-12-31 | CN¥238.98 Million ≈ $34.97 Million |
+25.20% |
| 2014-12-31 | CN¥190.87 Million ≈ $27.93 Million |
+12.66% |
| 2013-12-31 | CN¥169.42 Million ≈ $24.79 Million |
+8.29% |
| 2012-12-31 | CN¥156.45 Million ≈ $22.89 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Lifecome Biochemistry Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2497.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥155.42 Million | % |
| Other Comprehensive Income | CN¥69.59 Million | % |
| Other Components | CN¥340.47 Million | % |
| Total Equity | CN¥-26.27 Million | 100.00% |
Lifecome Biochemistry Co Ltd Competitors by Market Cap
The table below lists competitors of Lifecome Biochemistry Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Iress Ltd
AU:IRE
|
$882.87 Million |
|
Evertz Technologies Limited
TO:ET
|
$882.95 Million |
|
Yueyang Xingchang Petro-Chemical Co Ltd
SHE:000819
|
$883.51 Million |
|
CNB Financial Corporation
NASDAQ:CCNE
|
$883.70 Million |
|
Bangkok Airways Public Company Limited
BK:BA
|
$882.66 Million |
|
Evommune, Inc.
NYSE:EVMN
|
$882.45 Million |
|
Lotus Technology Inc.
NASDAQ:LOT
|
$882.32 Million |
|
Minerals 260 Ltd
AU:MI6
|
$882.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lifecome Biochemistry Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 411,287,522 to -26,267,391, a change of -437,554,913 (-106.4%).
- Net loss of 444,864,018 reduced equity.
- Dividend payments of 48,827,122 reduced retained earnings.
- Other comprehensive income increased equity by 69,591,066.
- Other factors decreased equity by 13,454,839.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-444.86 Million | -1693.6% |
| Dividends Paid | CN¥48.83 Million | -185.88% |
| Other Comprehensive Income | CN¥69.59 Million | +264.93% |
| Other Changes | CN¥-13.45 Million | -51.22% |
| Total Change | CN¥- | -106.39% |
Book Value vs Market Value Analysis
This analysis compares Lifecome Biochemistry Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥1.34 | CN¥38.82 | x |
| 2013-12-31 | CN¥1.45 | CN¥38.82 | x |
| 2014-12-31 | CN¥1.63 | CN¥38.82 | x |
| 2015-12-31 | CN¥2.05 | CN¥38.82 | x |
| 2016-12-31 | CN¥2.33 | CN¥38.82 | x |
| 2017-12-31 | CN¥4.86 | CN¥38.82 | x |
| 2018-12-31 | CN¥4.73 | CN¥38.82 | x |
| 2019-12-31 | CN¥4.96 | CN¥38.82 | x |
| 2020-12-31 | CN¥4.99 | CN¥38.82 | x |
| 2021-12-31 | CN¥4.68 | CN¥38.82 | x |
| 2022-12-31 | CN¥3.88 | CN¥38.82 | x |
| 2023-12-31 | CN¥2.67 | CN¥38.82 | x |
| 2024-12-31 | CN¥-0.17 | CN¥38.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lifecome Biochemistry Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -68.51%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (6.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 27.64% | 14.11% | 0.83x | 2.37x | CN¥27.60 Million |
| 2013 | 19.46% | 11.10% | 0.75x | 2.34x | CN¥16.03 Million |
| 2014 | 16.48% | 10.63% | 0.76x | 2.04x | CN¥12.36 Million |
| 2015 | 32.68% | 20.25% | 0.98x | 1.64x | CN¥54.21 Million |
| 2016 | 34.04% | 23.00% | 1.08x | 1.37x | CN¥65.23 Million |
| 2017 | 12.35% | 22.89% | 0.50x | 1.09x | CN¥16.36 Million |
| 2018 | 10.09% | 21.69% | 0.43x | 1.08x | CN¥652.49K |
| 2019 | 7.36% | 18.75% | 0.30x | 1.30x | CN¥-20.48 Million |
| 2020 | 5.65% | 14.02% | 0.32x | 1.27x | CN¥-33.31 Million |
| 2021 | -3.68% | -7.28% | 0.29x | 1.75x | CN¥-98.21 Million |
| 2022 | -20.60% | -37.21% | 0.27x | 2.08x | CN¥-182.29 Million |
| 2023 | -53.93% | -43.75% | 0.26x | 4.78x | CN¥-262.95 Million |
| 2024 | 0.00% | -68.51% | 0.44x | 0.00x | CN¥-442.24 Million |
Industry Comparison
This section compares Lifecome Biochemistry Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,109,695,154
- Average return on equity (ROE) among peers: 0.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lifecome Biochemistry Co Ltd (002868) | CN¥-104.52 Million | 27.64% | N/A | $882.85 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $108.47 Million | -73.31% | 2.66x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.66 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $-14.51 Million | 0.00% | 0.00x | $443.33 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $660.31 Million | 2.17% | 0.39x | $438.41 Million |
| Chengzhi Shareholding Co Ltd (000990) | $930.16 Million | 5.16% | 0.80x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $3.88 Billion | 15.17% | 0.04x | $3.86 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.19 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $12.48 Billion | 6.70% | 0.16x | $5.40 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $572.48 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.55 Billion | 15.33% | 0.16x | $1.90 Billion |
About Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, photovoltaic film products, etc.; veterinary drugs; and food preservatives. The company was founded in 2003 and is based in Pucheng, China.